Free Access
Med Sci (Paris)
Volume 29, Mars 2013
Page(s) 25 - 30
Section M/S Revues
Published online 13 March 2013
  1. Bitar D, Cauteren D Van, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis 2009 ; 15 : 1395–1401. [CrossRef] [PubMed] [Google Scholar]
  2. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients : data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009 ; 48 : 1695–1703. [CrossRef] [PubMed] [Google Scholar]
  3. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe : analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011 ; 17 : 1859–1867. [CrossRef] [PubMed] [Google Scholar]
  4. Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France : the RetroZygo Study (2005–2007). Clin Infect Dis 2012 ; 54 : S35–S43. [CrossRef] [PubMed] [Google Scholar]
  5. Ibrahim AS, Spellberg B, Walsh TJ, et al. Pathogenesis of mucormycosis. Clin Infect Dis 2012 ; 54 : S16–S22. [CrossRef] [PubMed] [Google Scholar]
  6. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008 ; 47 : 503–509. [CrossRef] [PubMed] [Google Scholar]
  7. Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against zygomycetes. Clin Infect Dis 2012 ; 54 : S61–S66. [CrossRef] [PubMed] [Google Scholar]
  8. Rammaert B, Lanternier F, Poirée S, et al. Diabetes and mucormycosis : a complex interplay. Diabetes Metab 2012 ; 38 : 193–204. [CrossRef] [PubMed] [Google Scholar]
  9. Ibrahim AS, Gebremariam T, Lin L, et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 2010 ; 77 : 587–604. [CrossRef] [PubMed] [Google Scholar]
  10. Yohai RA, Bullock JD, Aziz AA, et al. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994 ; 39 : 3–22. [CrossRef] [PubMed] [Google Scholar]
  11. Almyroudis NG, Sutton DA, Linden P, et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006 ; 6 : 2365–2374. [CrossRef] [PubMed] [Google Scholar]
  12. Mohindra S, Mohindra S, Gupta R, et al. Rhinocerebral mucormycosis : the disease spectrum in 27 patients. Mycoses 2007 ; 50 : 290–296. [CrossRef] [PubMed] [Google Scholar]
  13. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis : the last 30 years. Arch Intern Med 1999 ; 159 : 1301–1309. [CrossRef] [PubMed] [Google Scholar]
  14. Tedder M, Spratt JA, Anstadt MP, et al. Pulmonary mucormycosis : results of medical and surgical therapy. Ann Thorac Surg 1994 ; 57 : 1044–1050. [CrossRef] [PubMed] [Google Scholar]
  15. Arikan S, Sancak B, Alp S, et al. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008 ; 46 : 567–573. [CrossRef] [PubMed] [Google Scholar]
  16. Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica 2004 ; 89 : 207–214. [PubMed] [Google Scholar]
  17. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients : a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009 ; 200 : 1002–1011. [CrossRef] [PubMed] [Google Scholar]
  18. Lewis RE, Albert ND, Liao G, et al. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 2010 ; 54 : 1298–1304. [CrossRef] [PubMed] [Google Scholar]
  19. Lanternier F, et al. Mucormycose : résultats de l’étude Ambizygo. San Francisco : ICAAC, 2012 (abstract M-1707). [Google Scholar]
  20. Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with haematological malignancies : guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2012 ; 14 septembre (online). [PubMed] [Google Scholar]
  21. Almyroudis NG, Sutton DA, Fothergill AW, et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007 ; 51 : 2587–2590. [CrossRef] [PubMed] [Google Scholar]
  22. Ibrahim AS, Gebremariam T, Schwartz JA, et al. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009 ; 53 : 772–775. [CrossRef] [PubMed] [Google Scholar]
  23. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006 ; 50 : 126–133. [CrossRef] [PubMed] [Google Scholar]
  24. Verweij PE, González GM, Wiedrhold NP, et al. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J Chemother 2009 ; 21 : 272–281. [CrossRef] [PubMed] [Google Scholar]
  25. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008 ; 47 : 364–371. [CrossRef] [PubMed] [Google Scholar]
  26. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome therapy for mucormycosis (DEFEAT Mucor) study : a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012 ; 67 : 715–722. [CrossRef] [PubMed] [Google Scholar]
  27. Ferguson BJ, Mitchell TG, Moon R, et al. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 1988 ; 10 : 551–559. [CrossRef] [PubMed] [Google Scholar]
  28. Dannaoui E, Schwarz P, Lortholary O. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother 2009 ; 53 : 3549–3551. [CrossRef] [PubMed] [Google Scholar]
  29. Rammaert B, Lortholary O. Immunosuppresseurs et antifongiques : une interaction parfois positive ! Med Sci (Paris) 2010 ; 26 : 747–752. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.